Five Nova Scotia clean technology companies have been selected to participate in the inaugural cohort of Innovacorp’s CleanTech Accelerate Program, the Nova Scotia innovation agency has announced

Innovacorp exeucutives, including CEO Stephen Duff, for several years has been discussing ways to bring the mentoring available to IT companies, to other parts of the innovation community. Duff has

Lockheed Martin Canada said today it will expand its partnership with the Joint Economic Development Initiative, or Jedi, a not-for-profit organization that fosters economic development for First Nations in New Brunswick.

JEDI launched a targeted strategy in 2014 to help Aboriginal people to pursue businesses and careers in the aerospace and defence industry. The organization developed a unique

The third annual ProductCamp Atlantic, a gathering for product managers, marketing professionals, agile technology innovators, and thought leaders from across the region, will be held at the Innovacorp Enterprise Centre on Saturday, Oct. 22.

Using the “unconference” model, participants will exchange ideas with some of the top thought leaders in product management as they explore issues in product management and work to improve the way companies conceive, develop, and market products. Lunch and snacks are included, and a draw for prizes will wrap things up.

“How companies manage the business

Karma Gaming has sold its portfolio of lottery and instant games to Scientific Games Corp. of Las Vegas for an undisclosed price.

Scientific Games, which is listed on the Nasdaq Stock Exchange, announced the deal last week, saying it had taken on the portfolio of games and several employees of the Halifax company.

The buyer has established a development team in Halifax and is continuing to grow

Six Nova Scotia ocean technology companies have been selected to participate in Innovacorp’s Early Adopter Program, the provincial innovation agency said.

Each of the companies in the program will receive as much as $20,000 to help finance the first deployment and testing of a product with an early adopter customer.

The program participants’ customers include government entities, academic

Athletigen Technologies, a Halifax company dedicated to genetics for athletes, on Monday released its flagship product Iris.

Iris produces human performance insights developed from partnerships with world-class athletes and performance experts. The first of its kind, Iris is a suite of apps that analyzes the athlete’s genetic information. The athletes key in daily monitoring data allowing them

A familiar face on the East Coast startup circuit, Sean Wise had a limited time to answer a range of questions at Invest Atlantic and summed them up in a simple sentence: it’s a great time to be an entrepreneur.

Wise is a professor of entrepreneurship and venture capital at Ryerson University, and served as a consultant to Dragons’ Den when the CBC program was getting off the ground. And he’s

Our Jobs of the Week column this week features an opportunity for a developer interested in working for one of the hottest tech companies in the region.

The Fredericton agriculture technology company Resson, which this year announced it had raised US$11 million (C$14 million) from Monsanto Growth Ventures and other investors, is looking for a Senior User Interface/Front End Developer.

Founded

Cape Breton startups had to compete with Donald Trump, Jeff Hutcheson and Jim Balsillie at the Cape Breton Partnership’s Investor Summit on Thursday, but the young companies more than held their own.

The summit is the annual conference of the organization responsible for economic development on the island. The morning discussions highlighted Balsillie’s purchase and restoration of the Keltic

Pathogens’ growing antibiotic resistance is a global concern. Halifax drug discovery firm Appili Therapeutics Inc. is developing its own solutions, and scouring the world for potential drugs with which to grow the company.

CEO Kevin Sullivan said since Appili formed last year, its strategy has been to balance risk by acquiring drug candidates at different stages of development.

“Our strategy is